Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity

1. A compound of formula I:

wherein:

A, B, X, and D are defined as follows:

A is —CR 8 R 8 —,

where R 8 is independently selected from hydrogen, C 1-6 allyl, C 0-4 alkylCOR 11 and

where R 11 is selected from the group consisting of hydroxy, hydrogen, C 1-6 alkyl, —O— C 1-6 alkyl, benzyl, phenyl and C 3-6 cycloalkyl, where said alkyl, phenyl, benzyl, and cycloalkyl groups are unsubstituted or substituted with 1-3 substituents where said substituents are independently selected from the group consisting of halo, hydroxy, C 1-3 alkyl, C 1-3 alkoxy, —CO 2 H, —CO 2 —C 1-6 alkyl and trifluoromethyl;

B is —O—;

X is carbon;

D is carbon;

R 12 is selected from the group consisting of hydrogen, C 1-6 alkyl, benzyl and phenyl, and C 3-6 cycloalkyl

where said alkyl, phenyl, benzyl, and cycloalkyl groups are unsubstituted or substituted with 1-3 substituents where said substituents are independently selected from the group consisting of halo, hydroxy, C 1-3 alkyl, C 1-3 alkoxy, —CO 2 H, —CO 2 —C 1-6 alkyl, and trifluoromethyl,

R 13 is selected from the group consisting of hydrogen, C 1-6 alkyl, —O—C 1-6 alkyl, benzyl, phenyl and C 3-6 cycloalkyl where said alkyl, phenyl, benzyl, and cycloalkyl groups are unsubstituted or substituted with 1-3 substituents where said substituents are independently selected from the group consisting of halo, hydroxy, C 1-3 alkyl, C 1-3 alkoxy, —CO 2 H, —CO 2 —C 1-6 alkyl and trifluoromethyl,

R 14 is selected from the group consisting of hydroxy, C 1-6 alkyl, —O—C 1-6 alkyl, benzyl, phenyl and C 3-6 cycloalkyl where said alkyl, phenyl, benzyl, and cycloalkyl groups are unsubstituted or substituted with 1-3 substituents where said substituents are independently selected from the group consisting of halo, hydroxy, C 1-3 alkyl, C 1-3 alkoxy, —CO 2 H, —CO 2 —C 1-6 alkyl and trifluoromethyl,

Y is selected from the group consisting of —O—, —NR 12 —, —S—, —SO—, —SO 2 —, and —CR 11 R 11 —, —NSO 2 R 14 —, —NCOR 13 —, —NCONR 12 R 12 —, —CR 11 COR 11 —, —CR 11 OCOR 13 —and —CO—;

R 1 is selected from the group consisting of hydrogen, —C 1-6 alkyl, —C 0-6 alkyl-O—C 1-6 alkyl, —C 0-6 alkyl-S—C 1-6 alkyl, —(C 0-6 alkyl)-(C 3-7 cycloalkyl)-(C 0-6 alkyl), hydroxy, heterocycle, —CN, —NR 12 R 12 , —NR 12 COR 13 , —NR 12 SO 2 R 14 , —COR 11 , —CONR 12 R 12 , and phenyl,

where said alkyl and said cycloalkyl are unsubstituted or substituted with 1-7 substituents where said substituents are independently selected from the group consisting of:

(a) halo,

(b) hydroxy,

(c) —O—C 1-3 alkyl,

(d) trifluoromethyl,

(f) C 1-3 alkyl,

(g) —O—C 1-3 alkyl,

(h) —COR 11 ,

(i) —SO 2 R 14 ,

(j) —NHCOCH 3 ,

(k) —NHSO 2 CH 3 ,

(l) -heterocycle,

(m) ═O, and

(n) —CN, and

where said phenyl and heterocycle are unsubstituted or substituted with 1-3 substituents where said substituents are independently selected from the group consisting of halo, hydroxy, —COR 11 , C 1-3 alkyl, C 1-3 alkoxy and trifluoromethyl;

and where heteroclye is selected from the group consisting of benzoimidazolyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxetanyl, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinylyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methlenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof;

R 3 is selected from the group consisting of:

(a) hydrogen,

(b) C 1-3 alkyl, optionally substituted with 1-3 fluoro,

(c) —O—C 1-3 alkyl, optionally substituted with 1-3 fluoro,

(d) hydroxy,

(e) chloro,

(f) fluoro,

(g) bromo,

(h) phenyl, and

(i) heterocycle;

R 4 is selected from the group consisting of:

(a) hydrogen,

(b) C 1-3 alkyl, optionally substituted with 1-3 fluoro,

(c) —O—C 1-3 alkyl, optionally substituted with 1-3 fluoro,

(d) hydroxy,

(e) chloro,

(f) fluoro,

(g) bromo,

(h) phenyl, and

(i) heterocycle;

R 5 is selected from the group consisting of:

(a) C 1-6 alkyl, where alkyl is unsubstituted or substituted with 1-6 fluoro and optionally substituted with hydroxyl,

(b) —O—C 1-6 alkyl, where alkyl is unsubstituted or substituted with 1-6 fluoro,

(c) —CO—C 1-6 alkyl, where alkyl is unsubstituted or substituted with 1-6 fluoro,

(d) —S—C 1-6 alkyl, where alkyl is unsubstituted or substituted with 1-6 fluoro,

(e) -pyridyl, which is unsubstituted or substituted with one or more substituents selected from the group consisting of: halo, trifluoromethyl, C 1-4 alkyl, and COR 11 ,

(f) fluoro,

(g) chloro,

(h) bromo,

(i) —C 4-6 cycloalkyl,

(j) —O—C 4-6 cycloalkyl,

(k) phenyl, which is unsubstituted or substituted with one or more substituents selected from the group consisting of: halo, trifluoromethyl, C 1-4 alkyl, and COR 11 ,

(l) —O-phenyl, which is unsubstituted or substituted with one or more substituents selected from the group consisting of: halo, trifluoromethyl, C 1-4 alkyl, and COR 11 ,

(m) —C 3-6 cycloalkyl, where alkyl is unsubstituted or substituted with 1-6 fluoro,

(n) —O—C 3-6 cycloalkyl, where alkyl is unsubstituted or substituted with 1-6 fluoro,

(o) -heterocycle,

(p) —CN and

(q) —COR 11 ;

R 15 is selected from the group consisting of:

(a) hydrogen and

(b) C 1-6 alkyl, which is unsubstituted or substituted with 1-3 substituents where said substituents are independently selected from the group consisting of halo, hydroxy, —CO 2 H, —CO 2 C 1-6 alkyl, and —O—C 1-3 alkyl;

R 16 is selected from the group consisting of:

(a) hydrogen,

(b) C 1-6 alkyl, where alkyl is unsubstituted or substituted with 1-6 substituents where the substituents are chosen from the group: fluoro, C 1-3 alkoxy, hydroxy, and —COR 11 ,

(c) fluoro,

(d) —O—C 1-3 alkyl, where alkyl is unsubstituted or substituted with 1-3 fluoro,

(e) C 3-6 cycloalkyl,

(f) —O—C 3-6 cycloalkyl,

(g) hydroxy,

(h) —COR 11 and

(i) —OCOR 13 ,

or R 15 and R 16 may be joined together via a C 2-4 alkyl or a

C 0-2 alkyl-O—C 1-3 alkyl chain to form a 5-7 membered ring;

R 17 is selected from the group consisting of:

(a) hydrogen,

(b) C 1-6 alkyl, where alkyl may be unsubstituted or substituted with 1-6 substituents where said substituents are chosen from the group: fluoro, C 1-3 alkoxy, hydroxy, and —COR 11 ,

(c) COR 11 ,

(d) hydroxy, and

(e) —O—C 1-6 alkyl, where alkyl may be unsubstituted or substituted with 1-6 substituents where said substituents are chosen from the group consisting of fluoro, C 1-3 alkoxy, hydroxy, and —COR 11 ,

or R 16 and R 17 are joined together by a C 1-4 alkyl chain or a

C 0-3 alkyl-O—C 0-3 alkyl chain to form a 3-6 membered ring;

R 18 is selected from the group consisting of:

(a) hydrogen,

(b) C 1-6 alkyl, where alkyl is unsubstituted or substituted with 1-6 fluoro,

(c) fluoro,

(d) —O—C 3-6 cycloalkyl, and

(e) —O—C 1-3 alkyl, where alkyl is unsubstituted or substituted with 1-6 fluoro,

or R 16 and R 18 are joined together by a C 2-3 alkyl chain to form a 5-6 membered ring, where said alkyl are unsubstituted or substituted with 1-3 substituents where said substituents are independently selected from the group consisting of halo, hydroxy, —COR 11 , C 1-3 alkyl, and C 1-3 alkoxy,

or R 16 and R 18 are joined together by a C 1-2 alkyl-O—C 1-2 alkyl chain to form a 6-8 membered ring, where said alkyl are unsubstituted or substituted with 1-3 substituents where said substituents are independently selected from the group consisting of halo, hydroxy, —COR 11 , C 1-3 alkyl, and C 1-3 alkoxy,

or R 16 and R 18 are joined together by a —O—C 1-2 alkyl-O-chain to form a 6-7 membered ring, where said alkyl are unsubstituted or substituted with 1-3 substituents where said substituents are independently selected from the group consisting of halo, hydroxy, —COR 11 , C 1-3 alkyl, and C 1-3 alkoxy;

n is selected from 0, 1 and 2;

the dashed line represents a single or a double bond;

and pharmaceutically acceptable salts thereof and individual diastereomers thereof.

2. A compound of claim 1 of formula Ia:

wherein R 1 , R 3 , R 5 , R 15 , R 16 , R 18 , A, B, D, X, and Y are defined in claim 1 , and pharmaceutically acceptable salts and individual diastereomers thereof.

3. A compound of claim 1 of formula Ib:

wherein R 1 , R 3 , R 5 , R 16 , A, B, D, and X are defined in claim 1 , and pharmaceutically acceptable salts and individual diastereomers thereof.

4. A compound of claim 1 of formula Ic:

wherein R 1 , R 3 , R 5 and R 16 are defined in claim 1 , and pharmaceutically acceptable salts and individual diastereomers thereof.

5. A compound of claim 1 wherein Y is selected from the group consisting of: —O—, —CH 2 —, —S—, —SO—, and —SO 2 —.

6. A compound of claim 1 wherein R 1 is selected from the group consisting of

(1) —C 1-6 alkyl, which is unsubstituted or substituted with 1-6 substituents where said substituents are independently selected from the group consisting of:

(a) halo,

(b) hydroxy,

(c) —O—C 1-3 alkyl,

(d) trifluoromethyl and

(e) —COR 11 ,

(2) —C 0-6 alkyl-O—C 1-6 alkyl-, which is unsubstituted or substituted with 1-6 substituents where said substituents are independently selected from the group consisting of

(a) halo,

(b) trifluoromethyl and

(c) —COR 11 ,

(3) —(C 3-5 cycloalkyl)-(C 0-6 alkyl), which is unsubstituted or substituted with 1-7 substituents where said substituents are independently selected from the group consisting of

(a) halo,

(b) hydroxy,

(c) —O—C 1-3 alkyl,

(d) trifluoromethyl and

(e) —COR 11 , and

(4) phenyl or heterocycle which is unsubstituted or substituted with 1-3 substituents where said substituents are independently selected from the group consisting of

(a) halo,

(b) hydroxy,

(c) —O—C 1-3 alkyl,

(d) trifluoromethyl, and

(e) —COR 11 .

7. A compound of claim 6 wherein R 1 is C 1-6 alkyl which is unsubstituted or substituted with 1-5 substituents where said substituents are independently selected from the group consisting of:

(a) hydroxy, and

(b) fluoro.

8. A compound of claim 7 wherein R 1 is selected from the group consisting of:

(a) isopropyl,

(b) —CH(OH)CH 3 , and

(c) —CH 2 CF 3 .

9. A compound of claim 1 wherein D is carbon and R 3 is selected from:

(a) hydrogen

(b) halo

(c) hydroxy

(d) C 1-3 alkyl, where said alkyl is unsubstituted or substituted with 1-6 substituents independently selected from the group consisting of fluoro, and hydroxy,

(e) —COR 11 ,

(f) —CONR 12 R 12 ,

(g) -heterocycle,

(h) —NR 12 —SO 2 —NR 12 R 12 ,

(i) —NR 12 —SO 2 —R 14 ,

(j) —SO 2 —NR 12 R 12 ,

(k) -nitro and

(l ) —NR12R12.

10. A compound of claim 9 wherein R 3 is selected from the group consisting of:

(a) fluoro,

(b) trifluoromethyl and

(c) hydrogen.

11. A compound of claim 10 wherein D R 3 is

(a) fluoro or

(b) hydrogen.

12. A compound of claim 1 wherein X R 4 is selected from the group consisting of:

(a) hydrogen,

(b) trifluoromethyl and

(c) halo.

13. A compound of claim 12 wherein X R 4 is hydrogen.

14. A compound of claim 1 wherein R 5 is selected from the group consisting of

(a) C 1-3 alkyl substituted with 1-6 fluoro,

(b) chloro,

(c) bromo,

(d) —O-phenyl, which is unsubstituted or substituted with one or more substituents selected from the group consisting of: halo and trifluoromethyl,

(e) phenyl, which is unsubstituted or substituted with one or more substituents selected from the group consisting of: halo and trifluoromethyl, and

(f) —O—C 1-3 alkyl substituted with 1-6 fluoro.

15. A compound of claim 14 wherein R 5 is selected from the group consisting of:

(a) trifluoromethyl,

(b) trifluoromethoxy,

(c) bromo, and

(d) chloro.

16. A compound of claim 15 wherein R 5 is selected from trifluoromethyl and trifluoromethoxy.

17. A compound of claim 1 wherein R 15 is hydrogen or methyl.

18. A compound of claim 1 wherein R 16 is selected from the group consisting of:

(a) hydrogen,

(b) C 1-3 alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(c) —O—C 1-3 alkyl,

(d) fluoro, and

(e) hydroxy.

19. A compound of claim 18 wherein R 16 is selected from the group consisting of:

(a) hydrogen,

(b) trifluoromethyl,

(c) methyl,

(d) methoxy,

(e) ethoxy,

(f) ethyl,

(g) fluoro, and

(h) hydroxy.

20. A compound of claim 19 wherein R 16 is selected from the group consisting of:

(a) hydrogen,

(b) methyl, and

(c) methoxy.

21. A compound of claim 1 wherein R 18 is selected from the group consisting of:

(a) hydrogen,

(b) methyl, and

(c) methoxy.

22. One or more compounds of claim 1 selected from the group consisting of:

23. A compound of claim 1 wherein R 16 and R 18 are joined together by a —CH 2 CH 2 - chain or a —CH 2 CH 2 CH 2 - chain to form a cyclopentyl ring or a cyclohexyl ring.

24. A pharmaceutical composition which comprises an inert carrier and a compound of claim 1 .

25. A method for modulation of chemokine receptor CCR-2 activity in vitro which comprises the administration of an effective amount of the compound of claim 1 .

26. A method for treating atherosclerosis which comprises the administration to a patient of an effective amount of the compound of claim 1 .

27. A method for treating rheumatoid arthritis which comprises the administration to a patient of an effective amount of the compound of claim 1 .